<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834535</url>
  </required_header>
  <id_info>
    <org_study_id>R04-1123</org_study_id>
    <nct_id>NCT00834535</nct_id>
  </id_info>
  <brief_title>Cefdinir Capsules 300 mg, Non-fasting</brief_title>
  <official_title>A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Non-fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the relative bioavailability (rate and extent of absorption) of 300&#xD;
      mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of&#xD;
      OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a&#xD;
      single oral dose (1 x 300mg capsule) in healthy adult subjects administered under non-fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration)</measure>
    <time_frame>Blood samples collected over a 14 hour period.</time_frame>
    <description>Bioequivalence based on Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</measure>
    <time_frame>Blood samples collected over a 14 hour period.</time_frame>
    <description>Bioequivalence based on AUC0-t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)</measure>
    <time_frame>Blood samples collected over a 14 hour period.</time_frame>
    <description>Bioequivalence based on AUC0-inf.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefdinir Capsules 300 mg</intervention_name>
    <description>1 x 300 mg, single-dose non-fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMNICEF® Capsule 300 mg</intervention_name>
    <description>1 x 300 mg, single-dose non-fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Screening Demographics: All subjects selected for this study will be healthy men and&#xD;
             women 18 years of age or older at the time of dosing. the subject's body mass index&#xD;
             (BMI) should be 19 kg/m² - 30 kg/m², inclusive.&#xD;
&#xD;
          -  Screening procedures: Each subject will complete the screening process within 28 days&#xD;
             prior to Period I dosing. Consent documents for both the screening evaluation and HIV&#xD;
             antibody determination will be reviewed, discussed, and signed by each potential&#xD;
             participant before full implementation of screening procedures.&#xD;
&#xD;
        Screening will include general observations, physical examination, demographics, medical&#xD;
        and medication history, an electrocardiogram, sitting blood pressure and heart rate,&#xD;
        respiratory rate and temperature. The physical examination will include, but may not be&#xD;
        limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory, and central&#xD;
        nervous systems.&#xD;
&#xD;
        The screening clinical laboratory procedures will include:&#xD;
&#xD;
          -  Hematology: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet&#xD;
             count;&#xD;
&#xD;
          -  Clinical Chemistry: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total&#xD;
             bilirubin, total protein, and alkaline phosphatase;&#xD;
&#xD;
          -  HIV antibody and hepatitis B surface antigen and hepatitis C antibody screens;&#xD;
&#xD;
          -  Urinalysis: by dipstick; full microscopic examination if dipstick positive; and&#xD;
&#xD;
          -  Urine Drug Screen: ethyl alcohol, amphetamines, barbiturates, benzodiazepines,&#xD;
             cannabinoids, cocaine metabolites, opiates and phencyclidine.&#xD;
&#xD;
          -  Serum Pregnancy Screen (female subjects only)&#xD;
&#xD;
        If female and:&#xD;
&#xD;
          -  of childbearing potential, is practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condom with&#xD;
             spermicide, diaphragm with spermicide, intrauterine device (IUD) or abstinence; or&#xD;
&#xD;
          -  is postmenopausal for at least 1 year; or&#xD;
&#xD;
          -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a recent history of drug or alcohol addiction or abuse.&#xD;
&#xD;
          -  Subjects with the presence of a clinically significant disorder involving the&#xD;
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,&#xD;
             endocrine, or neurologic system(s) or psychiatric disease (as determined by the&#xD;
             clinical investigators).&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are outside the accepted reference&#xD;
             range and when confirmed on re-examination are deemed to be clinically significant.&#xD;
&#xD;
          -  Subjects demonstrating a reactive screen for hepatitis B surface antigen, hepatitis C&#xD;
             antibody or HIV antibody.&#xD;
&#xD;
          -  Subjects demonstrating a positive drug abuse screen when screened for this study.&#xD;
&#xD;
          -  Female subjects demonstrating a positive pregnancy screening.&#xD;
&#xD;
          -  Female subjects who are currently breastfeeding.&#xD;
&#xD;
          -  Subjects with a history of allergic response(s) to cefdinir or related drugs.&#xD;
&#xD;
          -  Subjects with a history of clinically significant allergies including drug allergies.&#xD;
&#xD;
          -  Subjects with a clinically significant illness during the 4 weeks prior to Period I&#xD;
             dosing (as determined by the clinical investigators).&#xD;
&#xD;
          -  Subjects who currently use or report using tobacco products within 3 months of Period&#xD;
             I dose administration.&#xD;
&#xD;
          -  Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in&#xD;
             the 28 days prior to Period I dosing.&#xD;
&#xD;
          -  Subjects who report donating greater than 150 mL of blood within 28 days prior to&#xD;
             Period I dosing. All subjects will be advised not to donate blood for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
          -  Subjects who have donated serum (e.g. serumpheresis) within 14 days prior to Period I&#xD;
             dosing. All subjects will be advised not to donate serum for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
          -  Subjects who report receiving any investigational drug within 28 days prior to Period&#xD;
             I dosing.&#xD;
&#xD;
          -  Subjects who report taking any systemic prescription medication in the 14 days prior&#xD;
             to Period I dosing.&#xD;
&#xD;
          -  Subjects who report an intolerance of direct venipuncture.&#xD;
&#xD;
          -  Subjects who report consuming an abnormal diet during the 28 days prior to Period I&#xD;
             dosing.&#xD;
&#xD;
          -  Subjects who report having difficulty fasting or consuming standardized meals.&#xD;
&#xD;
          -  Female subjects who report using implanted or injected hormonal contraceptives (birth&#xD;
             control) during the 6 months prior to Period I dosing.&#xD;
&#xD;
          -  Female subjects who report using oral hormonal contraceptives (birth control) during&#xD;
             the 14 days prior to Period I dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Carlson, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>East Grand Forks</city>
        <state>Minnesota</state>
        <zip>56721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>June 18, 2009</results_first_submitted>
  <results_first_submitted_qc>June 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2009</results_first_posted>
  <last_update_submitted>August 14, 2009</last_update_submitted>
  <last_update_submitted_qc>August 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefdinir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cefdinir (Test) First</title>
          <description>300 mg Cefdinir Capsules test product dosed in first period followed by 300 mg Omnicef® Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="P2">
          <title>Omnicef® (Reference) First</title>
          <description>300 mg Omnicef® Capsules reference product dosed in first period followed by 300 mg Cefdinir Capsules test product dosed in the second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout of 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cefdinir (Test) First</title>
          <description>300 mg Cefdinir Capsules test product dosed in first period followed by 300 mg Omnicef® Capsules reference product dosed in the second period.</description>
        </group>
        <group group_id="B2">
          <title>Omnicef® (Reference) First</title>
          <description>300 mg Omnicef® Capsules reference product dosed in first period followed by 300 mg Cefdinir Capsules test product dosed in the second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration)</title>
        <description>Bioequivalence based on Cmax.</description>
        <time_frame>Blood samples collected over a 14 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cefdinir (Test)</title>
            <description>300 mg Cefdinir Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Omnicef® (Reference)</title>
            <description>300 mg Omnicef® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration)</title>
          <description>Bioequivalence based on Cmax.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2081.37" spread="537.12"/>
                    <measurement group_id="O2" value="2045.43" spread="481.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model containing factors for sequence of products, subjects within sequence, periods, and products was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>100.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>93.98</ci_lower_limit>
            <ci_upper_limit>108.17</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</title>
        <description>Bioequivalence based on AUC0-t.</description>
        <time_frame>Blood samples collected over a 14 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cefdinir (Test)</title>
            <description>300 mg Cefdinir Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Omnicef® (Reference)</title>
            <description>300 mg Omnicef® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)</title>
          <description>Bioequivalence based on AUC0-t.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10700.97" spread="2328.12"/>
                    <measurement group_id="O2" value="11121.51" spread="2215.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model containing factors for sequence of products, subjects within sequence, periods, and products was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>96.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.14</ci_lower_limit>
            <ci_upper_limit>100.22</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)</title>
        <description>Bioequivalence based on AUC0-inf.</description>
        <time_frame>Blood samples collected over a 14 hour period.</time_frame>
        <population>All participants that completed the study had their samples analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cefdinir (Test)</title>
            <description>300 mg Cefdinir Capsules test product dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Omnicef® (Reference)</title>
            <description>300 mg Omnicef® Capsules reference product dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)</title>
          <description>Bioequivalence based on AUC0-inf.</description>
          <population>All participants that completed the study had their samples analyzed.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11219.51" spread="2304.28"/>
                    <measurement group_id="O2" value="11560.85" spread="2237.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The ANOVA model containing factors for sequence of products, subjects within sequence, periods, and products was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p&lt;0.05).</non_inferiority_desc>
            <param_type>Ratio of the T/R geometric mean x 100</param_type>
            <param_value>96.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.8</ci_lower_limit>
            <ci_upper_limit>100.49</ci_upper_limit>
            <estimate_desc>Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

